Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC-Reference-Cited by-同舟云学术

Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC

Published:2024-04-21 Issue:6 Volume:24 Page:347-361
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Gemelli Maria¹,Albini Adriana²,Catalano Gianpiero³,Incarbone Matteo⁴,Cannone Maria⁵,Balladore Emanuela⁵,Ricotta Riccardo¹,Pelosi Giuseppe⁵⁶

Affiliation:

1. Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy

2. Departement of Scientific Directorate, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy

3. Radiation Oncology Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy

4. Department of Surgery, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy

5. Inter-Hospital Division of Pathology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy

6. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2344648

Reference112 articles.

1. The biology and management of non-small cell lung cancer

2. Targeting ALK in lung cancer: rationale, progress, and prospects;Shaw AT;Nat Rev Clin Oncol,2013

3. Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

4. METEG (MET exon 14 skipping alterations): a review of clinical and mechanistic data;Peters S;Oncology,2021

5. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol;Awad MM;H&O,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers by Adding Repurposed Itraconazole and Cilostazol;Cells;2024-07-10